These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Internal radiotherapy in prostatic carcinoma; disappointing long-term results of of retropubic Iodine-125 implantation]. Batterman JJ; Boon TA; Zeijlemaker BY Ned Tijdschr Geneeskd; 1997 Jan; 141(3):171-2. PubMed ID: 9053772 [No Abstract] [Full Text] [Related]
3. [Initial experiences with iodine-121 implantation in 41 patients with prostatic carcinoma]. Battermann JJ; Boon TA; Beijert M; de Voogt HJ Ned Tijdschr Geneeskd; 1987 Sep; 131(36):1573-6. PubMed ID: 3670438 [No Abstract] [Full Text] [Related]
4. Permanent transperineal iodine--125 implantation. Stokes SH; Real JD; Adams PW; Kan W Ala Med; 1990 Nov; 60(5):18-20. PubMed ID: 2291449 [No Abstract] [Full Text] [Related]
5. Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer. Tanaka N; Fujimoto K; Asakawa I; Hirayama A; Yoneda T; Yoshida K; Hirao Y; Hasegawa M; Konishi N Brachytherapy; 2010; 9(4):300-6. PubMed ID: 20708440 [TBL] [Abstract][Full Text] [Related]
6. Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications. Steggerda MJ; van der Poel HG; Moonen LM Brachytherapy; 2010; 9(4):319-27. PubMed ID: 20691644 [TBL] [Abstract][Full Text] [Related]
7. [The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity]. Pommier P; Delannes M; LeFloch O; Bernier V; Baron MH; Thomas L; Malet C; Bonnet J; Louisot P; Aletti P; Goubard O; Chemin A; Chirat F; Lebivic S; Montbarbon X; Bachaud JM; Votron L; Lasbareilles O; Desmettre O; Bringeon G; Gassa F; Peiffert D Cancer Radiother; 2006 Dec; 10(8):559-64. PubMed ID: 16959520 [TBL] [Abstract][Full Text] [Related]
9. [The treatment of localized cancer of the prostate using radioactive iodine implants]. Fradet Y; Laverdière J; Beaudoin L Union Med Can; 1985 Sep; 114(9):737-9. PubMed ID: 4060345 [No Abstract] [Full Text] [Related]
11. [Initial experiences with iodine-125 implantation in 41 patients with prostate carcinoma]. Veen RE Ned Tijdschr Geneeskd; 1987 Nov; 131(46):2099-100. PubMed ID: 3683643 [No Abstract] [Full Text] [Related]
12. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125. Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031 [TBL] [Abstract][Full Text] [Related]
13. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125. Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317 [TBL] [Abstract][Full Text] [Related]
14. Prostatic 125I implantation--new approach in the management of prostatic cancer. Kim RY; Bueschen AJ J Med Assoc State Ala; 1983 Apr; 52(10):21-5. PubMed ID: 6842112 [No Abstract] [Full Text] [Related]
15. Development of a new design (125)I-brachytherapy seed for its application in the treatment of eye and prostate cancer. Saxena SK; Sharma SD; Dash A; Venkatesh M Appl Radiat Isot; 2009; 67(7-8):1421-5. PubMed ID: 19282194 [TBL] [Abstract][Full Text] [Related]
16. Counterpoint: there is a dose-response relationship in the low-dose rate brachytherapy management of prostate cancer. Stock RG Brachytherapy; 2010; 9(4):293-6; discussion 299. PubMed ID: 20833593 [No Abstract] [Full Text] [Related]
17. Interstitial I-125 implantation in the management of localized prostatic cancer. Whitmore WF Prog Clin Biol Res; 1984; 153():513-27. PubMed ID: 6473411 [No Abstract] [Full Text] [Related]
18. Simple, accurate, safe, and cost-effective percutaneous transperineal template technique for permanent 125iodine interstitial brachytherapy of prostate cancer. Kumar PP; Good RR; Hussain MB; Bartone FF Strahlenther Onkol; 1986 Nov; 162(11):713-9. PubMed ID: 3097859 [TBL] [Abstract][Full Text] [Related]
19. Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? Morris WJ; Halperin R; Spadinger I Brachytherapy; 2010; 9(4):289-92; discussion 297-8. PubMed ID: 20739226 [No Abstract] [Full Text] [Related]